Dr. Steven Treon, MD, MA, PhD, FRCP, FACP
Professor, Harvard Medical School
Lead physician, Dana-Farber Cancer Institute
Director, Bing Center for Waldenstrom’s macroglobulinemia

Dr. Treon is the Director of the Bing Center for Waldenstrom’s Macroglobulinemia at Dana-Farber Cancer Institute (DFCI), a Professor of Medicine at Harvard Medical School, and Chair of the WM Clinical Trials Group. Dr. Treon earned a BA (Biology), MS (Biochemistry), PhD (Cancer Immunology), and MD with honors from Boston University, and MA from Harvard Medical School. He completed an Internal Medicine residency at Boston University Medical Center, Hematology/Medical Oncology Fellowship at Massachusetts General Hospital, and post-doctoral training at DFCI.

In 1999, Dr. Treon initiated a WM clinic at DFCI which cares for nearly 2,500 WM patients annually. Using whole-genome sequencing, Dr. Treon’s laboratory first identified highly recurring activating mutations in MYD88 and CXCR4 in WM patients and was the first to report that Bruton’s tyrosine kinase (BTK) was a downstream target of the MYD88 L265 mutation, resulting in a study leading to the first-ever approval of a drug (ibrutinib) for WM. Dr. Treon has published extensively on topics in WM and related disorders, with over 300 peer-reviewed original reports, reviews, editorials, and chapters in high-impact journals and textbooks. He has been the principal organizer of the biennial International Workshops on WM since 2000 and the International Patient and Physician Summits since 2003.

Dr. Treon's scientific work in WM has earned “Best of the American Society of Hematology” designations at the 2011 and 2013 Annual Meetings of the American Society of Hematology. In 2017, Dr. Treon was elected as a fellow to the Royal College of Physicians in London, and in 2018, as a fellow to the American College of Physicians. Currently, he is spear-heading large clinical trials within the United States directed at COVID-19 with BTK inhibitors.